Risk Anal. 2021 Feb;41(2):393-406. doi: 10.1111/risa.13665.
Despite a strong global commitment, polio eradication efforts continue now more than 30 years after the 1988 World Health Assembly resolution that established the Global Polio Eradication Initiative (GPEI), and 20 years after the original target of the year 2000. Prior health economic analyses estimated incremental net benefits of the GPEI of 40-50 billion in 2008 U.S. dollars (US$2008, equivalent to 48-59 billion US$2019), assuming the achievement of polio eradication by 2012. Given the delays in achieving polio eradication and increased costs, we performed an updated economic analysis of the GPEI using an updated integrated global model, and considering the GPEI trajectory as of the beginning of 2020. Applying similar methods and assuming eradication achievement in 2023, we estimate incremental net benefits of the GPEI of 28 billion US$2019, which falls below the prior estimate. Delays in achieving polio eradication combined with the widescale introduction of relatively expensive inactivated poliovirus vaccine significantly increased the costs of the GPEI and make it less cost-effective, although the GPEI continues to yield expected incremental net benefits at the global level when considered over the time horizon of 1988-2029. The overall health and financial benefits of the GPEI will depend on whether and when the GPEI can achieve its goals, when eradication occurs, the valuation method applied, and the path dependence of the actions taken. Reduced expected incremental net benefits of the GPEI and the substantial economic impacts of the COVID-19 pandemic pose large financial risks for the GPEI.
尽管全球各国做出了坚定承诺,但在 1988 年世界卫生大会通过全球根除脊髓灰质炎倡议(GPEI)决议 30 多年后,以及最初设定的 2000 年根除目标 20 年后,脊髓灰质炎根除工作仍在继续。此前的卫生经济分析估计,假设到 2012 年实现根除目标,GPEI 在 2008 年(2008 年美元,相当于 480-590 亿美元)将产生 400-500 亿美元的增量净效益。鉴于根除工作的延迟和成本的增加,我们使用更新的综合全球模型对 GPEI 进行了更新的经济分析,并考虑了截至 2020 年初的 GPEI 轨迹。采用类似的方法,并假设在 2023 年实现根除,我们估计 GPEI 的增量净效益为 280 亿美元(2019 年美元),低于此前的估计。根除工作的延迟加上相对昂贵的灭活脊髓灰质炎疫苗的广泛使用,大大增加了 GPEI 的成本,使其成本效益降低,尽管从 1988 年至 2029 年的时间范围内考虑,GPEI 仍在全球范围内产生预期的增量净效益。GPEI 的总体健康和经济效益将取决于 GPEI 是否以及何时能够实现其目标、何时根除、所应用的估值方法以及所采取行动的路径依赖性。GPEI 的预期增量净效益降低以及 COVID-19 大流行的巨大经济影响给 GPEI 带来了巨大的财务风险。